Study of upper respiratory tract bacterial flora: first report. Variations in upper respiratory tract bacterial flora in patients with acute upper respiratory tract infection and healthy subjects and variations by subject age

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Masatoshi KonnoKimiko Ubukata

Abstract

With the appearance of penicillin-resistant Streptococcus pneumoniae, there has been increasing debate concerning antimicrobial treatments for acute upper respiratory tract infection (AURTI) and acute otitis media in children. This study compares the nasopharyngeal bacterial flora in patients with AURTI (AURTI group; 710 subjects) and healthy subjects (HS group; 380 subjects). The comparisons were made between subjects aged 6 years or younger (0-6 subgroup: 330 subjects), between 7 and 74 years (7-74 subgroup: 668 subjects), and 75 years and older (92 subjects), because the subjects were subgrouped as described above dependent on the maturity of the protective immunity. In the HS group 7-74 subgroup, viridans group streptococci, Staphylococcus aureus, coagulase-negative staphylococci, and Corynebacterium sp. with a detection rate of 10% or more were classified as normal nasal flora (NNF), and Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis were classified as drum cavity pathogens (DCP). In the 0-6 subgroup, although the detection rate for DCP bacteria in the AURTI group tended to be high, it did not reach a significant difference, whereas the detection rate for NNF bacteria wa...Continue Reading

References

Jun 5, 1998·Scandinavian Journal of Primary Health Care·R K GunnarssonM Söderström
Jan 4, 2001·International Journal of Pediatric Otorhinolaryngology·K TanoS Hellström
May 4, 2004·Pediatrics·UNKNOWN American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media

❮ Previous
Next ❯

Citations

Aug 2, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T TenenbaumB Henrich
Feb 28, 2007·Antimicrobial Agents and Chemotherapy·Sho TakahataShigeru Hoshiko
Jul 4, 2012·Applied and Environmental Microbiology·Melinda M PettigrewJoshua P Metlay
Nov 12, 2013·The Journal of Infection·Chidi N ObasiJames Gern
Jul 1, 2009·Tropical Medicine & International Health : TM & IH·Christian L ColesJames M Tielsch
Sep 28, 2017·Clinical & Experimental Ophthalmology·Emil D KurniawanPenelope J Allen
Apr 1, 2018·Acta Paediatrica·Urban Johansson KostenniemiSven-Arne Silfverdal
Apr 25, 2014·Clinical and Vaccine Immunology : CVI·Amelieke J H CremersGerben Ferwerda
Jun 7, 2008·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Vladimir MikhailovichAlexander Zasedatelev
Jan 12, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Pratama Novan Y IUNKNOWN Suharjono
Mar 2, 2021·Japanese Journal of Infectious Diseases·Tomohiro OishiChikara Nakahama
Oct 9, 2021·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Nicolai Østergaard NielsenTejs Ehlers Klug

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.